



December 2024

Unless otherwise stated, Performance, Portfolio Breakdowns and Net Asset information as at: 31-Dec-2024. All other data as at 10-Jan-2025.

This document is marketing material. For Investors in the UK. Investors should read the KIID/PRIIPs document and prospectus prior to investing, and should refer to the prospectus for the funds full list of risks.

#### **FUND OVERVIEW**

- The Fund aims to achieve positive absolute returns through a combination of capital growth and income on your investment regardless of market conditions.
- The Fund seeks to gain at least 70% of its investment exposure to equity securities (e.g. shares) and equity-related securities of companies (including derivatives), or giving exposure to securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. There are no geographical restrictions on the Fund's investments., which may be based in developed or emerging markets. In selecting the Fund's investments, the investment adviser (IA) will use fundamental analysis, focusing on a variety of different strategies.
- The Fund will invest at least 70% of its assets in equity securities, other equity-related securities and when determined appropriate, fixed-income securities (such as bonds), money market instruments (MMIs) (i.e. debt securities with short term maturities) deposits and cash.

### **RISK INDICATOR**

**CAPITAL AT RISK:** The value of investments and the income from them can fall as well as rise and are not guaranteed. Investors may not get back the amount originally invested.

# **KEY RISKS:**

- Investment risk is concentrated in specific sectors, countries, currencies or companies.
   This means the Fund is more sensitive to any localised economic, market, political, sustainability-related or regulatory events.
- The value of equities and equity-related securities can be affected by daily stock market movements. Other influential factors include political, economic news, company earnings and significant corporate events.
- 'Absolute Return' funds may not move in line with market trends or fully benefit from a
  positive market environment. Emerging markets are generally more sensitive to
  economic and political conditions than developed markets.
- Derivatives may be highly sensitive to changes in the value of the asset on which they are based and can increase the size of losses and gains, resulting in greater fluctuations in the value of the Fund. The impact to the Fund can be greater where derivatives are used in an extensive or complex way.
- Counterparty Risk: The insolvency of any institutions providing services such as safekeeping of assets or acting as counterparty to derivatives or other instruments, may expose the Fund to financial loss.
- Liquidity Risk: Lower liquidity means there are insufficient buyers or sellers to allow the Fund to sell or buy investments readily.

### **KEY FACTS**

Target<sup>†</sup>1: 3 Month SOFR Compounded in Arrears

plus 26.1 basis point spread

Asset Class: Equity

Fund Launch Date: 03-Aug-2023 Share Class Launch Date: 03-Aug-2023

Fund Base Currency: USD

Share Class Currency: GBP

Use of Income: Accumulating

Net Assets of Fund (M): 16.74 USD

Morningstar Category: SFDR Classification: Other
Domicile: Luxembourg
ISIN: LU2353382547

Management Company: BlackRock

(Luxembourg) S.A.

## FEES AND CHARGES

Annual Management Fee: 1.00%

Ongoing Charge: 1.08% Performance Fee: 20.00%

### **DEALING INFORMATION**

Dealing Frequency: Daily, forward pricing basis

Settlement: Trade Date + 3 days

## **PORTFOLIO CHARACTERISTICS**

Price to Book Ratio: -51.45x


Price to Earnings Ratio: -7.84x


Number of Holdings: 82

# **PORTFOLIO MANAGER(S)**

Erin Xie Xiang Liu

# **BlackRock**





CUMULATIVE & ANNUALISED PERFORMANCE										
		CUMULATIVE (%)						ANNUALISED (% p.a.)		
		1m	3m	6m	YTD	<b>1</b> y	Зу	5у	Since Inception	
9	Share Class	-0.37	1.48	2.94	6.31	6.31	-	-	6.39	
	Target <sup>†1</sup>	0.41	1.27	2.71	5.64	5.64	-	-	5.70	

The figures shown relate to past performance. Past performance is not a reliable indicator of current or future performance and should not be the sole factor of consideration when selecting a product or strategy. Share Class and Benchmark performance displayed in GBP, hedged share class benchmark performance is displayed in USD. Performance is shown on a Net Asset Value (NAV) basis, with gross income reinvested where applicable. The return of your investment may increase or decrease as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. **Source:** BlackRock


Share Class


BSF Health Sciences Absolute Return FundClass I2 Hedged British Pound
Target<sup>11</sup>


3 Month SOFR Compounded in Arrears plus 26.1 basis point spread

# **BlackRock**

TOP 10 HOLDINGS (%)	
STRYKER CORP	2.53%
WATERS CORP	2.36%
LABCORP HOLDINGS INC	2.27%
BOSTON SCIENTIFIC CORP	2.25%
ABBOTT LABORATORIES	1.90%
ARGENX SE ADR	1.76%
GILEAD SCIENCES INC	1.64%
INTUITIVE SURGICAL INC	1.53%
ROCHE HOLDING PAR AG	1.52%
ASTRAZENECA ADR REPRESENTING .5 PL	1.46%
Total of Portfolio	19.22%
Holdings subject to change	









### **GLOSSARY**

**SFDR Classification: Article 8:** Products that promote environmental or social characteristics and promote good governance practices. **Article 9:** Products that have sustainable investments as an objective and follow good governance practices. **Other:** Products that do not meet the criteria to be classified as Article 8 or 9.

**Price to Earnings:** A valuation ratio of a company's current share price compared to its per-share earnings in the current forecast year, calculated as current share price divided by current earnings per share.

**Price to Book Ratio:** represents the ratio of the current closing price of the share to the latest quarter's book value per share.

#### IMPORTANT INFORMATION:

In the UK and Non-European Economic Area (EEA) countries: this is issued by BlackRock Investment Management (UK) Limited, authorised and regulated by the Financial Conduct Authority. Registered office: 12 Throgmorton Avenue, London, EC2N 2DL. Tel: + 44 (0)20 7743 3000. Registered in England and Wales No. 02020394. For your protection telephone calls are usually recorded. Please refer to the Financial Conduct Authority website for a list of authorised activities conducted by BlackRock.

BSF Funds: BlackRock Strategic Funds (BSF) is an open-ended investment company established and domiciled in Luxembourg which is available for sale in certain jurisdictions only. BSF is not available for sale in the U.S. or to U.S. persons. Product information concerning BSF should not be published in the U.S. BlackRock Investment Management (UK) Limited is the Principal Distributor of BSF and may terminate marketing at any time. In the UK, subscriptions in BSF are valid only if made on the basis of the current Prospectus, the most recent financial reports and the Key Investor Information Document, and in EEA and Switzerland subscriptions in BSF are valid only if made on the basis of the current Prospectus, the most recent financial reports and the Packaged Retail and Insurance-based Investment Products Key Information Document (PRIIPs KID) which are available in registered jurisdictions and local language where they are registered, these can be found at www.blackrock.com on the relevant product pages. Prospectuses, Key Investor Information Documents, PRIIPs KID and application forms may not be available to investors in certain jurisdictions where the Fund in question has not been authorised. Investors should understand all characteristics of the funds objective before investing, if applicable this includes sustainable disclosures and sustainable related characteristics of the fund as found in the prospectus, which can be found www.blackrock.com on the relevant product pages for where the fund is registered for sale. For information on investor rights and how to raise complaints please go to https://www.blackrock.com/corporate/compliance/investor-right available in in local language in registered jurisdictions.

Any research in this document has been procured and may have been acted on by BlackRock for its own purpose. The results of such research are being made available only incidentally. The views expressed do not constitute investment or any other advice and are subject to change. They do not necessarily reflect the views of any company in the BlackRock Group or any part thereof and no assurances are made as to their accuracy.

This document is for information purposes only and does not constitute an offer or invitation to anyone to invest in any BlackRock funds and has not been prepared in connection with any such offer.

©2025 BlackRock, Inc. All Rights reserved. BLACKROCK, BLACKROCK SOLUTIONS and iSHARES are trademarks of BlackRock, Inc. or its affiliates. All other trademarks are those of their respective owners.